Join us on Feb. 28 for the @sitcancer #LearnACI live virtual Women’s Malignancies program featuring in-depth education on all aspects of clinical implementation of IO for women’s malignancies. Learn more and register:

SMARCA4 inhibition enhances NK-mediated killing of senescent cells and can be combined with cisplatin to treat ovarian cancer https://t.co/8rqSeyYjTb https://t.co/Xbj1T539wm @ScienceAdvances @VirinderReen @DmitriyZamarin

Our ⁦@NRGonc⁩ GY017 trial of neoadjuvant or concurrent atezolizumab+CRT in locally advanced cervical cancer is out! Neoadjuvant IO led to favorable outcomes and persistence of tumor-resident TCRs in blood. Implications for optimal IO and RT sequence.

The ASCI’s 2025 Active and International elected members https://t.co/6hCWY31RYX Congratulations to new members from @IcahnMountSinai - @JoshuaBrodyMD @DmitriyZamarin @keithsigelmd

This paper is the result of an incredibly fun collaboration with @SantagataMDPhD and Peter Sorger. Led by the fantastic @TanjinaKader with @JiaRenLin, we provide a pre-cancer atlas of Fallopian tube precursors to HGSOC. Don't miss our cbioportal entry of all the data!

Check out our new story! Mechanisms of innate and adaptive immune activation in cancer cells deficient in SMARCA4. Thank you to the multiple collaborators that made it possible. @neoviral @bengrbm @gonen_mithat @ChiappinelliLab

New #JITC article: Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors https://t.co/syGlCdKQbj @diwakardavar @Farnaldez3 @PatelOncology @DmitriyZamarin

Special thanks to our amazing collaborators @AnnaVaharautio and @DmitriyZamarin for their invaluable contributions, and to the DoD, NIH, and @TheMarkFdn for supporting this research.

What an inspiring 4 days at the 15th HHMT Intl Forum on Ovarian Cancer!Sharing our research and collaborating to overcome ovarian cancer @KunleOdunsiMD @ErnstLengyel @ronny_drapkin @DmitriyZamarin @afarkkila @StephanieLheur5 @rugangzhang @OCRAhope@OvarianCancerUK #forourpatients

Ovarian Cancer, watch out: the biennial Rivkin Center-AACR Ovarian Cancer Symposium is about to start! Honored to be on this year’s organizing committee and look forward to the amazing scientific and education sessions. ⁦@RivkinCenter⁩ ⁦@AACR⁩

Thank you @CancerResearch for the opportunity to participate in this patient education series! #OvarianCancerAwarenessMonth

Excited and honored to co-lead our newly-established Center of Excellence for Gynecologic Cancer @MountSinaiNYC with the amazing @StephanieVBlank.

Ovarian cancer is one of several gynecologic malignancies, impacting about 300,000 women each year. During #OvarianCancerAwarenessMonth, learn how CRI-funded researchers, including CRI Lloyd J. Old STAR @StacyMalaker @Yale @YaleChem, are making an impact:

My colleagues and I have prepared the best lineup for speakers in Translational Oncology @NRGonc @theNCI @NCItreatment @KimmelCancerCtr @TJUHospital @DmitriyZamarin All are welcome!

Love ovarian cancer? Hate ovarian cancer? You’re not alone! Submit your abstracts to the Biennial Rivkin-AACR Ovarian Cancer Research symposium! This will be a fantastic meeting with the latest and greatest in ovarian cancer research.

@tsialater @ggardnermd @DmitriyZamarin 👏👏👏

5. Overall, even in highly-responsive tumors such as dMMR, TME-based features can aid with patient selection. Notably, our identified parameters should be quite straightforward to implement using standard IHC assays and are certainly worthy exploring in larger cohorts.

4. On a genetic level, there were some additional interesting signals, though neither overall TMB or mechanism of dMMR (genetic or epigenetic) were predictive.

3. A combination of these two parameters resulted in a highly predictive multivariable model with PPV and NPV both over 90%.

2. PD-L1 expression was not predictive of response, while pre-existing immune response, evidenced by presence of dysfunctional T cells and interaction of dysfunctional T cells with PD-L1 positive cells in the tumor were strongly and independently associated with response.